Indications
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Composition
- Active substance
- mavorixafor
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xolremdi
- Active substance
- mavorixafor
- ATC code
- L03AX24
- Therapeutic area
- Primary Immunodeficiency Diseases
- Marketing authorisation holder
- X4 Pharmaceuticals GmbH
- Status